These synergic effects are supported by recent literature demonstrating that a combination based on splicing and BCL2 inhibition is effective in other hematological malignancies, including multiple myeloma [72] and chronic lymphocytic leukemia [73]. Here, BCL2 is linked to plasma cell myeloma.